We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Algorithm Helps Detect Cancer Genes

By Biotechdaily staff writers
Posted on 14 Jun 2006
An algorithm has been developed that enhances the ability to detect cancer genes. More...
The algorithm has been applied to map tumor-suppressor genes involved in lung cancer.

Research using gene-chips found that chromosomal segments, when deleted in single or both copies of genomes in a group of cancer patients, point to locations of tumor-suppressor genes implicated in the cancer. Researchers at New York University's Courant Institute of Mathematical Sciences (New York, NY, USA) focused on automatic methods for reliable detection of these genes, their locations, and boundaries. The algorithm they developed uses data from Affymetrix (Santa Clara, CA, USA) gene-chips to pinpoint genes involved in cancer, even when the genomes have other unrelated deletions.

In order to validate their algorithm, the researchers produced a high fidelity in silico model of cancer, and checked how well they could detect the right genes, as they modified various parameters of the model. They applied the algorithm to patient data and were able to discover many genes already known in the literature, in addition to several others that were statistically significant. The algorithm may be suitable for the detection of oncogenes, which when mutated or overexpressed can promote cancer growth.

The study was conducted by Professor Bud Mishra of NYU's Courant Institute and School of Medicine (New York, NY, USA) and colleagues. The findings are to be reported in the July 2006 issue of the American Journal of Human Genetics.

Members of the New York University group, Dr. Salvatore Paxia, and Dr. Thomas Anantharaman are in the process of creating a simpler interface for the software, providing interoperability across many different chip technologies, so that it can become publicly available.



Related Links:
Courant Institute of Mathematical Sciences, NYU
School of Medicine NYU

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Clinical Informatics Platform
CLARION™
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.